Industry anger as off-label Avastin rears its head again
This article was originally published in SRA
Executive Summary
After the legislative upheavals in France and Italy, the Avastin v Lucentis saga has reared its head again in the UK, after clinical commissioning groups (CCGs) called on the government and NHS England to support doctors wanting to prescribe Roche's Avastin (bevacizumab) off label for wet age-related macular degeneration (AMD) in place of Novartis' more costly Lucentis (ranibizumab)1.